Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Your Crackers mate .
Salty too.
Hoggin make your mind up if your a Boar or a Sow
Yes BUT are you confident that Kevin and Suzy have the skills to make the negotiations to get these over the line when the time is due, its evident you know the science and frankly god knows we could really do with you on the Board OR at least someone with your skill sets.
If you are looking at 2.5yrs that's the cash done again and another placing if not managed correctly, the current runway is out before then and we have the lab acquisition to consider at what cost. Will that be a another crap negotiation that dilutes us again?
I totally share your confidence in the potential of these products but i don't have the confidence based on the dire handling of both 201 and 301, no set timelines, no set milestones stated or reported on, that Kevin and Suzy can do this alone. For me i really want to see two top draw appointments, one to replace KA and one to add further value PLUS an experienced contracts manager of sorts if either of the two new appointments are also not as strong in that area. The business desperately needs this in my opinion. We cant do the same things and expect a different outcome as i see it.
Would you support in trying to lobby both Kevin and Suzy to consider this? Suzy is NOT a formidable negotiator which is what Kevin thinks and that really concerns me, surely you must be thinking the same? You cant possibly be happy with the handling of 201 can you? Your thoughts on the above points would really be of value. Thanks
Porks'
I've been fairly critical of the BOD over the last week, but this is now a good time to kick off a material come-back. Those fortunate to be able to average down have now done so.
If the work on the new TNBC compound has concluded satisfactorily, then this data analysis should be expedited, to make the decision to transition it to the SPV stage, or not. There is now plenty in the kitty to fund the 500K VAL development side costs for one of these SPV compounds, and such news would be welcomed, not least by myself.
Any compounds reaching the SPV stage will be lead-optimised, and so will be ready to commence efficacy and toxicity analysis, as they progress to the IND (Investigational New Drug) stage. VAL has set tight deadlines of around 2.5 years to do this, and the team do know what is required to then out-license them. In fact I know that VAL has formed a list of key questions that large pharma have specifically told them to answer, when going back to market these.
These new compounds are not 201. They are novel, hopefully first-in-class, compounds, with a completely fresh (up to) 20-year patent. They are also in areas of unmet/poorly-met clinical need, and so they may ultimately qualify for fast-track designations. The oncology ones will also qualify for S9 preclinical development packages, which are quicker and more streamlined. This is all good. You can feel good about investing in these - they are worthwhile.
For the more medically agnostic investor, the 2-3 intervening time between Lead Optimization and IND application is a stage of exponential value accretion. Entering an SPV and optimized, I'd "value" something around 5-10MUSD, which could be larger in one go, than the current MCap itself. I know an AIM outfit who generate compounds for large Pharma, at this stage, for 10MUSD, per pop. Once in an SPV, the candidate can be sold at any point, up to, and including, the IND submission stage. So the value rises from this initial figure, to a package deal, which could ultimately be worth anything up to 500MUSD in milestones, plus single digit royalties (currently). Again - these are NOT 201 - there is NO baggage and there should be NO patent issues.
The new compound RNSs that I would like to see will include target, Mode-of-Action, and a brief synopsis of the panel of tests that have thus far been undertaken. Investors will also want to see the global market figures. Key also will be the originating Lab/partner. For the TNBC candidate, for example, a world-class institute such as King's College or UCL will add significant provenance to the test article, and will help attract significant investment going forward.
@Mer400
The example you give of DNL proves how difficult this market is even when you get a drug to commercialisation. As you say its trading well under its cash value but that’s because as per most biotech’s they eat money whilst trying to develop drugs.
With VAL its cash burn is £1.25m a year. The placing extends its cash runway, so it has call it up to two years wriggle room at the current burn rate. Its newer university pipeline drugs will still be years off commercialisation so income can only come from successful licencing of the legacy assets.
201 is now effectively locked in on an exclusive to THX without any timelines. It could sit with THX paying nothing and raising nothing for years and Share holders will soon tire of that situation. 301 out in Japan with no update for years and 401 without update. There is great potential here, but it needs strong negotiating hands, and we don’t have that currently IMO unless board additions are made. They can’t negotiate for toffee.
The lab plan can add revenues, but the question will be how they fund the first one. Will it be via equity or some other merger deal, how good a deal, just don’t know the detail yet.
In terms of the increased shares in issue in principle you would expect some kind of bounce from 10p once everything resolves but markets remain ugly and IMO still a risk short term of a quick pump and those 10p buyers taking a quick 10-20% short term. Time will tell. Currently see how events unfold cash burn continues if they don’t get a grip of licencing deals.
Finally, I will give this a further go once dust settles if the BOD is strengthened, I regret not selling all my stock now at 35p but hindsight is a wonderful thing but, I want to see those appointments made, the Suzy and Kevin show is not enough for me now, but this can be sorted. Let’s hope so anyhow.
GLA
All buys from 8.30am
Mer,
Suzy has spent the last three years explaining they do not do clinical trials and are looking to outsource the drugs by finding a partner to pay for the trials. It may have taken long but as long as 201 gets done the rest is a bonus.
Also it appears you do not under market caps which is the most basic part of investing in AIM.
The triple breast cancer drug if successful should add millions to the market cap which is rock bottom.
Fully funded for over 1 year and about 2 years if Cenkos takes the warrants at a later date and if the deal gets done.
This is a very strong buy from me here. 2p downside and 60p upside in the next 3-6 months imo. Do your own research.
Guys I really would like Val to succeed. I’d love to see 201 in the treatment of prostate cancer but look at the figures 201 trial finish in 2019?? 401 before that and they haven’t started another trial as far as I’m aware. If these drugs were as good as we were led to believe 201 next trial phase would be complete same with 401. We’d be seeing royalty payments coming through and we wouldn’t need to fundraise. Another pharma on aim has a share price of 10p but it has about 18m in cash 2 drugs passed with EMA now being sold and one passed with FDA being sold in the USA. One of only 3 companies on AIM to have a drug passed by the FDA. They a yet to make a profit and if you want a rock bottom share this I’d there right now as the CEO recently stated they MIGHT need to raise more funds before they reach profitability but this could be a loan and not dilution. Then he left the company go figure. DNL